This HTML5 document contains 100 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n23http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/mesh/concept/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/chebi/
n9http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/wikipedia/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/pharmgkb/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/kegg-compound/
n7http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n34http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/pubchem-substance/
n5http://linked.opendata.cz/resource/drugbank/patent/
n35http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/drugbank/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/iuphar/
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/guide-to-pharmacology/
n11http://www.drugs.com/cdi/
n14http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00966/identifier/national-drug-code-directory/
n16http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00966
rdf:type
n3:Drug
n3:description
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
n3:dosage
n8:271B454E-363D-11E5-9242-09173F13E4C5 n8:271B454C-363D-11E5-9242-09173F13E4C5 n8:271B454D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11558835 # Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12462282 # Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20502601 # Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20448797
n3:group
approved investigational
n3:halfLife
Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
n3:indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
n3:manufacturer
n9:271B453F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00966 n35:DB00966
dcterms:title
Telmisartan
adms:identifier
n22:Telmisartan n23:59391 n25:DB00966 n26:9434 n27:592 n28:C07710 n29:592 n30:PA451605 n31:65999 n32:D00627 n33:0597-0039-37 n34:46505370
n3:mechanismOfAction
Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT<sub>1</sub>-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPAR&gamma;, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPAR&gamma; activators.
n3:packager
n9:271B453D-363D-11E5-9242-09173F13E4C5 n9:271B453E-363D-11E5-9242-09173F13E4C5 n9:271B453B-363D-11E5-9242-09173F13E4C5 n9:271B453C-363D-11E5-9242-09173F13E4C5
n3:patent
n5:6358986 n5:2060624 n5:5591762
n3:routeOfElimination
Following either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
n3:synonym
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid 4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid Telmisartan 4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid 4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid BIBR 277 Micardis
n3:toxicity
Intravenous LD<sub>50</sub> in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
n3:volumeOfDistribution
* 500 L
n12:hasAHFSCode
n13:24-32-08
n3:mixture
n15:271B4539-363D-11E5-9242-09173F13E4C5 n15:271B453A-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Highly bound to plasma proteins (&gt;99.5%), mainly albumin and a1-acid glycoprotein. Binding is not dose-dependent.
n3:synthesisReference
# Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20502601
n19:hasConcept
n20:M0223750
foaf:page
n11:telmisartan.html n14:telmisartan.htm n16:mic1592.shtml
n3:IUPAC-Name
n4:271B4553-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4559-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4558-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4555-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4556-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4557-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4551-363D-11E5-9242-09173F13E4C5 n4:271B4569-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B454F-363D-11E5-9242-09173F13E4C5 n4:271B4552-363D-11E5-9242-09173F13E4C5 n4:271B456B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4550-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n17:C09CA07
n3:H-Bond-Acceptor-Count
n4:271B455F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4560-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B455A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B455B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B455D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B455C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B455E-363D-11E5-9242-09173F13E4C5
n3:absorption
Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B456C-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
144701-48-4
n3:clearance
* >800 mL/min
n3:containedIn
n24:271B454A-363D-11E5-9242-09173F13E4C5 n24:271B454B-363D-11E5-9242-09173F13E4C5 n24:271B4548-363D-11E5-9242-09173F13E4C5 n24:271B4549-363D-11E5-9242-09173F13E4C5 n24:271B4546-363D-11E5-9242-09173F13E4C5 n24:271B4547-363D-11E5-9242-09173F13E4C5 n24:271B4544-363D-11E5-9242-09173F13E4C5 n24:271B4545-363D-11E5-9242-09173F13E4C5 n24:271B4542-363D-11E5-9242-09173F13E4C5 n24:271B4543-363D-11E5-9242-09173F13E4C5 n24:271B4540-363D-11E5-9242-09173F13E4C5 n24:271B4541-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4565-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4567-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4568-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B456A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4564-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4563-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4566-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4554-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4561-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4562-363D-11E5-9242-09173F13E4C5